Methadone Linked to Lower One-Year Death Risk Than Buprenorphine

Surviving an opioid overdose leaves a person at sharply elevated risk of dying, and the medication-assisted treatment started in that window carries real consequences.

A new Canadian study of 5,882 overdose survivors found that those who began methadone were less likely to die over the next year than those who began buprenorphine-naloxone. Outside experts responding to the study argue the gap between the two medications is not the number worth focusing on.

The research, led by Robert A. Kleinman, MD, MSc, of the Centre for Addiction and Mental Health in Toronto, was published in JAMA Network Open and reported by MedPage Today.

What the Study Found

Of the 375 people who died within a year, opioid overdose was identified as a cause in 264. Opioid overdose deaths specifically accounted for 3.8% of the methadone group and 5.1% of the buprenorphine-naloxone group.

Retention differed too, though not by much in absolute terms. Median time to discontinuation was 25 days for methadone and 16 days for buprenorphine-naloxone. Time to a first subsequent opioid overdose did not differ significantly between the groups.

Why the Experts Pushed Back

In an accompanying commentary, Evan Wood, MD, PhD, of the University of British Columbia, and Leen Naji, MD, PhD, of the University of Arizona, questioned whether methadone is genuinely superior.

Their argument rests on the study’s per-protocol analyses, which looked at outcomes while people were actually receiving treatment. There, the difference in death risk was not statistically significant, and the hazard of opioid overdose was higher for people who started methadone.

No mortality difference appeared at all among people who had not received opioid agonist treatment in the preceding three years. Wood and Naji argued the most notable result is not the comparison between medications.

Roughly 6% of participants died within a year, more than a quarter had another overdose, and nearly 90% discontinued treatment during follow-up. They urged researchers and policymakers to spend less energy on the relative merits of each medication and more on why staying in treatment is so unappealing to most patients.

Medication-Assisted Treatment Options Compared

Both medications are opioid agonists, meaning they act on the same receptors that heroin and fentanyl do, but in a controlled and long-acting way that prevents withdrawal and reduces cravings without producing the same intensity of effect.

Methadone is a full agonist. It is dispensed through licensed opioid treatment programs, usually daily at first, and dosing is titrated over weeks under clinical supervision.

Buprenorphine-naloxone is a partial agonist combined with naloxone to discourage misuse. It can be prescribed in office-based settings, which makes it easier to access, but starting it requires care.

Because buprenorphine binds opioid receptors more strongly than the opioids already present, beginning it too soon can trigger precipitated withdrawal, which is abrupt and severe. Clinicians manage this by timing the first dose or using low-dose initiation protocols.

Neither is a taper to be managed alone at home. The choice between them depends on withdrawal severity, fentanyl exposure, pregnancy, other medications, prior treatment history, and what is available nearby.

Why Medical Detox Matters After an Overdose

The retention figures are the practical argument for supervised care. When median time in treatment is measured in weeks and nearly nine in ten people leave within a year, the transition into medication is where support matters most.

Tolerance falls quickly during any period of reduced use, which means a dose that was previously survivable can be fatal on return to use. A medically supervised setting monitors that risk, manages withdrawal symptoms with medication, screens for co-occurring conditions, and can start an opioid agonist without the guesswork that leads to precipitated withdrawal.

Withdrawal management alone is not treatment. Detox stabilizes someone physically; what determines the next year is whether medication and support continue after discharge.

Finding Medical Detox

If you or someone you know has recently survived an overdose, the days that follow are the ones that matter most. Ask any program whether it starts medication for opioid use disorder before discharge and how it arranges continuing care, since that handoff is where most people are lost.

Never attempt alcohol or benzodiazepine detox without medical supervision. Withdrawal from either can cause seizures and, in the case of alcohol, delirium tremens, both of which can be fatal.

Detox.com’s directory lists medically supervised detox programs by location, with details on medical staffing, substances treated, and insurance accepted. Call 800-996-6135(Sponsored) to speak with a treatment specialist today.